Insider Trading April 2, 2026

Ingredion Director Executes Small Sale, Receives Annual Retainer in Stock

Jorge A. Uribe reports minor sale alongside director compensation; company updates include dividend, executive shift, board change, and protein research tie-up

By Sofia Navarro INGR
Ingredion Director Executes Small Sale, Receives Annual Retainer in Stock
INGR

Ingredion Inc. director Jorge A. Uribe reported a small open-market sale of company shares and receipt of stock as annual director retainer. The filings show a fractional sale worth $83, issuance of 380 shares as compensation, tax-withholding of part of the retainer, and the insider's updated direct and indirect holdings. The disclosures arrive as Ingredion announces a dividend payment, a temporary CFO appointment, a board retirement and replacement, and a research collaboration focused on protein discovery.

Key Points

  • Insider sale of 0.74 shares at $112.66 and receipt of 380-share director retainer valued at $42,810 with 67.26 shares withheld for taxes ($7,577).
  • Uribe's post-transaction holdings: 13,236.8574 shares direct, 6,137 shares indirect via Cafedan Investments Ltd Trust.
  • Company updates: $0.82 quarterly dividend payable April 21, 2026; interim CFO appointment; long-serving director retirement and board replacement; collaboration with Shiru on AI-driven protein discovery.

Ingredion Inc. (NYSE: INGR) disclosed a recent set of insider transactions and corporate updates in filings and company announcements that update the ownership and leadership picture at the ingredient solutions company.

According to a Form 4 filing, director Jorge A. Uribe sold 0.74 shares of Ingredion common stock at $112.66 per share, generating proceeds of $83. The sale was recorded alongside the planned issuance of shares that comprise the annual outside director retainer.

On March 31, 2026, Uribe received 380 shares of Ingredion common stock as part of that annual retainer, with each share valued at $112.66, bringing the retainer's total to $42,810. From the retainer award, the company withheld 67.26 shares to satisfy applicable tax obligations; the withheld shares were valued at $7,577.

Following the sale and the retainer issuance and withholding, the filings show Uribe's direct ownership totals 13,236.8574 shares of Ingredion common stock. In addition to his direct holdings, Uribe holds an indirect stake of 6,137 shares through Cafedan Investments Ltd Trust.

These insider actions are reported as Ingredion trades at a price-to-earnings ratio of 10.03 and carries a market capitalization of $7.09 billion. An InvestingPro analysis referenced in the filings characterizes the stock as appearing undervalued at current price levels and assigns the company a "GREAT" financial health score. The analysis also notes that the company has maintained dividend payments for 29 consecutive years, with the current yield at 2.91%.

Separately, the company has declared a quarterly dividend of $0.82 per share, payable on April 21, 2026, to shareholders of record as of April 1, 2026.

Ingredion also reported changes to its senior finance leadership. Jason Payant has been named Interim Chief Financial Officer, succeeding James D. Gray, whose resignation is effective March 31. Payant, who joined Ingredion in 2012, will continue in his role as Vice President, Finance, Global Texture & Healthful Solutions while serving as interim CFO.

Board composition will change as well. Gregory B. Kenny is retiring after more than 21 years of service, and Siobhán Talbot will join the board to fill the vacancy created by Kenny's departure.

On the research and development front, Ingredion is expanding its capabilities through a collaboration with Shiru that focuses on AI-driven protein discovery for a range of food and nutrition products. The partnership will use Shiru's database of natural protein sequences to develop functional proteins and prebiotics.


Summary

Director Jorge A. Uribe reported a fractional sale valued at $83 and received 380 shares as an annual retainer on March 31, 2026, with 67.26 shares withheld for taxes. After these transactions he holds 13,236.8574 shares directly and 6,137 shares indirectly through Cafedan Investments Ltd Trust. The company has also confirmed a quarterly dividend, an interim CFO appointment, a long-tenured director retirement with a replacement, and a research collaboration focused on protein discovery.

Key points

  • Insider transaction: Jorge A. Uribe sold 0.74 shares at $112.66 and was issued 380 shares as the annual outside director retainer (380 shares valued at $42,810), with 67.26 shares withheld for taxes ($7,577).
  • Ownership update: Uribe now directly owns 13,236.8574 shares and indirectly owns 6,137 shares via Cafedan Investments Ltd Trust.
  • Corporate developments: Ingredion declared a $0.82 quarterly dividend payable April 21, 2026; Jason Payant named interim CFO effective with James D. Gray's resignation on March 31; Gregory B. Kenny retiring after over 21 years and Siobhán Talbot joining the board; collaboration with Shiru on AI-driven protein discovery.

Risks and uncertainties

  • Leadership transition: The resignation of the CFO and appointment of an interim CFO introduces short-term leadership change in the finance function.
  • Board turnover: The retirement of a long-tenured director and the appointment of a new director will alter board composition and experience dynamics.
  • Tax and compensation effects: Withholding of retainer shares to cover taxes reduced the net new shares issued to the director; this affects the effective dilution and ownership calculations.

Risks

  • Finance leadership change with the resignation of James D. Gray and interim appointment of Jason Payant could create short-term uncertainty in the finance organization.
  • Board composition will shift following the retirement of Gregory B. Kenny and the appointment of Siobhán Talbot, altering director experience and oversight dynamics.
  • Tax withholding on the director retainer (67.26 shares withheld, $7,577) reduces net issued shares and affects ownership dilution calculations.

More from Insider Trading

Tango Therapeutics R&D Head Executes $572k Share Sale Under Prearranged Plan Apr 2, 2026 Hinge Health Executive Chairman Disposes of $1.9M in Shares; Board and Analyst Moves Add Context Apr 2, 2026 Remitly Business Chief Executes Option Exercise, Sells 10,000 Shares Under 10b5-1 Plan Apr 2, 2026 Klaviyo Director Executes $3.88M Series A Sale, Converts Series B Shares Amid Buyback and Product Push Apr 2, 2026 Southland Holdings Co-COO Purchases 29,177 Shares as Company Battles Large Loss and Litigation Settlement Apr 2, 2026